相关实验视频

Updated: Jan 16, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

mAb104抗体-药物结合物的特征向瘤选择性的HER2表皮质

Sagun Parakh^1,2,3, Nhi Huynh¹, Laura D Osellame^1,3

¹Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne 3084, Australia.

|September 27, 2025

概括

新型抗体药物合物 (ADC),mAb104-ADC,在表达HER2的癌症中显示出强大的抗瘤活性. 这种向疗法在各种癌症类型中表现出有效性,包括那些对现有治疗方法耐药的癌症.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
药物开发药物开发

背景情况:

抗HER2抗体104 (mAb104) 针对一个独特的瘤特异性表位.
mAb104表现出有限的正常组织结合和瘤细胞内化,使其适合抗体-药物合物 (ADC) 开发.

研究的目的:

评估基于mAb104的ADC的结合性质和临床前疗效.
评估mAb104-ADCs在各种HER2表达瘤中的治疗潜力.

主要方法:

mAb104与细胞毒性有效载荷的结合:松胺埃姆坦辛 (DM1),埃克萨特干衍生物 (DX8951) 和单甲基奥里斯丁E (MMAE).
在临床前模型中进行了体外细胞毒性测定和体内安全性和有效性研究.
在HER2表达水平的频谱中对抗瘤活性的评估.

主要成果:

mAb104-ADCs在体外显示了剂量依赖的细胞毒性.
单剂量mAb104-DX8951的使用在体内是安全的,最高可达10mg/kg.
在不同的瘤类型中观察到强大且持续的抗瘤效应,具有不同的HER2表达.
mAb104-DX8951在耐特苏祖马布的HER2阳性乳腺癌和低HER2表达的癌症中显示出显著的疗效.

结论:

mAb104-ADCs对HER2表达瘤的向治疗具有前景.
这些发现支持mAb104-ADCs在瘤学中的临床开发潜力.

关键词:

在HER2中,HER2是HER2.抗体药物合物抗体药物合物标志性标志性标志性标志性异米尔提尼布耐药性异米尔提尼布耐药性它们对trastuzumab有耐药性.

更多相关视频

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction

Published on: September 14, 2018

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...